GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Inclusion Criteria: * Age ≥ 18 years. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at the time of study treatment initiation. * Have pathologically confirmed diagnosis of STK11 mutant NSCLC. STK11 mutation will be based on subject's local clinically accredited laboratory testing (Clinical Laboratory Improvement Amendments \[CLIA\]-certified) using deoxyribonucleic acid (DNA) sequencing test. * Must have progressed on a pembrolizumab containing regimen and eligible for continuing pembrolizumab post-progression as determined by treating physician. * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L. * Platelets ≥ 100 x 10\^9/L. * Hemoglobin ≥ 9 g/dL. * Estimated glomerular filtration rate (GFR) (measured or calculated with Cockroft and Gault formula) \> 45mL/min. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) (ALT and AST ≤ 5 x ULN is acceptable if liver metastases are present). * Total bilirubin ≤ 1.5 x ULN. For patients with well documented Gilbert's syndrome, total bilirubin ≤ 3 x ULN with direct bilirubin within normal range. * Troponin-I ≤ ULN and B-type natriuretic peptide test (BNP) \< 200 pg/mL. * Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) (institutional limit). * Patients must have measurable disease as defined in Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Participants of child-bearing potential must agree to use adequate contraceptive…